Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07215390 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Jun 2027 to Sep 25, 2027 Trial sites expanded: 68 → 78 locations · Primary completion moved earlier from Sep 25, 2027 to Jun 25, 2027 · Completion moved earlier from Mar 23, 2028 to Nov 2027 · 2 morev7 Show 5 more changesShow less
    • Trial sites expanded: 68 → 78 locations
    • Primary completion moved earlier from Sep 25, 2027 to Jun 25, 2027
    • Completion moved earlier from Mar 23, 2028 to Nov 2027
    • Completion pushed from Nov 2027 to Mar 23, 2028
    • Start date: Sep 29, 2025 to Jun 23, 2025
  2. Start date: Jun 23, 2025 to Sep 29, 2025 Primary completion date: Jun 2027 to Sep 25, 2027 · Completion date: Nov 2027 to Mar 23, 2028v6 Show 2 more changesShow less
    • Primary completion date: Jun 2027 to Sep 25, 2027
    • Completion date: Nov 2027 to Mar 23, 2028
  3. Trial sites expanded: 43 → 68 locationsv5
  4. Trial sites expanded: 38 → 43 locationsv4
  5. Study sites: 22 to 38v3
  6. Study sites: 2 to 22v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Trial Details
NCT Number NCT07215390
Lead Sponsor Apellis Pharmaceuticals, Inc.
Conditions Geographic Atrophy Secondary to Age-related Macular Degeneration
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov